Open AccessMinimal residual disease and b-cell subpopulation monitoring in acute b-lymphoblastic leukaemia patients treated on rall-2016 protocol
Author(s) -
Irina Galtseva,
Ю. О. Давыдова,
Е Н Паровичникова,
Olga A. Gavrilina,
В В Троицкая,
Nikolay Kapranov,
Ksenia Nikiforova,
Galina Isinova,
Ksenija I. Zarubina,
Andrey N. Sokolov,
В Г Савченко
Publication year - 2021
Publication title -
gematologiâ i transfuziologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-3042
pISSN - 0234-5730
DOI - 10.35754/0234-5730-2021-66-2-192-205
Subject(s) - minimal residual disease , medicine , immunophenotyping , bone marrow , flow cytometry , b cell , cohort , gastroenterology , oncology , immunology , antibody
. The Russian multicentre trial on treatment of Acute Lymphoblastic Leukaemia (ALL) in adults (RALL-2016) regulates a centralised detection of minimal residual disease (MRD) on days 70 (end of induction II), 133 (end of consolidation III) and 190 (end of consolidation V). Aim — the assessment of tumour cell clearance and normal B-cell precursor, mature B-cell and plasma cell dynamics. Materials and methods . The study period of December 2016 — August 2019 covered 59 B-ALL patients; the control cohort included four allogeneic blood stem cell donors. The MRD detection was performed with bone marrow samples in flow cytometry. Results . The patient majority have reached MRD-negativity at control timepoints, 60.4, 75.6 and 91.2% on days 70, 133 and 190, respectively. No correlation was observed between MRD values and tumour cell immunophenotype. B-cell precursors were undetected in 54.4, 38.8 and 59.4% patients on days 70, 133 and 190, respectively. Mature B-cells were fewer compared to donors’ on days 133 and 190. The relative plasma cell count did not differ significantly over therapy and between patients and donors. Conclusion . The RALL-2016 protocol facilitates MRD-negativity in the patient majority despite reduced cytostatic intensity.